M&A Deal Summary |
|
---|---|
Date | 2015-09-30 |
Target | Scioderm |
Sector | Life Science |
Buyer(s) | Amicus Therapeutics |
Deal Type | Add-on Acquisition |
Deal Value | 229M USD |
Advisor(s) | J.P. Morgan Securities (Financial) Cooley (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2002 |
Sector | Life Science |
Employees | 517 |
Revenue | 399M USD (2023) |
Amicus Therapeutics is a biotechnology company at the forefront of therapies for rare and orphan diseases. Amicus Therapeutics was founded in 2002 and is based in Princeton, New Jersey.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Life Science) | 1 of 2 |
Type (Add-on Acquisition) | 1 of 2 |
State (North Carolina) | 1 of 1 |
Country (United States) | 1 of 2 |
Year (2015) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2018-09-20 |
Celenex
Columbus, Ohio, United States Celenex is a clinical stage gene therapy company. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. Celenex is based in Columbus, Ohio. |
Buy | $175M |